Inkemia, a Mab company in the biotechnology sector, increases capital to continue growing on the international market and does not rule out making acquisitions in 2017.
About Inkemia
INKEMIA is a group of high-tech SMEs, born in 1997, whose activity is focused on the generation and exploitation of knowledge to obtain new products, processes, technologies and services for the pharmaceutical, chemical and biotechnological industries. Since Inkemia was listed on the Mab in 2012, it has been in a process of expansion, opening its first foreign subsidiary in Brazil in 2014 and in 2016 in the USA. The company is aware of the importance of growing abroad and has decided to create a new subsidiary in London, and its English second-generation biofuels subsidiary, Inkemia Advanced BF, will definitively enter the British SME market (AIM) in 2017.
On the capital increase
Inkemia has initiated the capital increase process aimed at raising €2.2M, issuing a maximum of one million (1,060,318) shares of €0.10 par value, with a share premium of €2.00 per share. Currently, Inkemia's market capitalisation is €55.73M and the market price of the shares is €2.15.
The funds will be used to strengthen subsidiaries in the US -Inkemia Green Chemicals, based in Houston and focused on introducing green solvents into industrial sectors- and the UK -Inkemia Advanced BF, based in London and focused on exploiting advanced biofuels technology. The expansion will also enhance the internationalisation process.
The company has also announced the creation of a new subsidiary specialising in synthetic biology. In addition, Inkemia has announced the creation of a new subsidiary specialising in synthetic biology.
Inkemia looks to European markets in 2017
Inkemia's UK subsidiary Inkemia Advanced BF is expected to enter the UK SME market in 2017, with an approximate valuation of up to €75M.
Two of its investees, Mind the Byte and Vytrus Biotech, also plan to go public.
Vytrus Biotech, of which Inkemia has a 21% stake, has set itself a 2018 deadline for listing, with potential markets including AIM, MAB and even Euronext.
Mind the Byte, in which Inkemia controls 5.5 percent, also plans to list on the MAB or AIM, but without such an immediate date.
Inkemia goes to the capital increase in Bioo
Inkemia has a Knowledge Capital fund, which invests in biotech companies. The latest company in which it has participated, in December 2016, is Bioo, a company that generates electricity from plants. The capital raised will be used primarily for investment in R&D in the areas of mechatronics and biotechnology, in addition to conducting pilot tests for the market launch of its first products.
In addition to Bioo, in 2016 Inkemia has increased capital in its investees LeanbioS.L., Pharmamel S.L. and Clinical Research
If you are looking for investors, you want to buy or selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.
Clever global exits on Mab and grows 11% on its first day